vs
Artisan Partners Asset Management Inc.（APAM）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
Artisan Partners Asset Management Inc.的季度营收约是Prestige Consumer Healthcare Inc.的1.2倍（$335.5M vs $283.4M），Artisan Partners Asset Management Inc.净利率更高（35.2% vs 16.5%，领先18.7%），Artisan Partners Asset Management Inc.同比增速更快（12.9% vs -2.4%），Artisan Partners Asset Management Inc.自由现金流更多（$171.6M vs $75.3M），过去两年Artisan Partners Asset Management Inc.的营收复合增速更高（12.7% vs 1.2%）
阿蒂森伙伴资产管理公司（Artisan Partners）是总部位于美国威斯康星州密尔沃基的资产管理机构，除美国本土外，还在都柏林、香港、伦敦、新加坡、悉尼设有办公室，为全球客户提供专业的资产管理服务。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
APAM vs PBH — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $335.5M | $283.4M |
| 净利润 | $118.1M | $46.7M |
| 毛利率 | — | 55.5% |
| 营业利润率 | 39.2% | 29.1% |
| 净利率 | 35.2% | 16.5% |
| 营收同比 | 12.9% | -2.4% |
| 净利润同比 | 34.9% | -23.5% |
| 每股收益（稀释后） | $1.36 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $335.5M | $283.4M | ||
| Q3 25 | $301.3M | $274.1M | ||
| Q2 25 | $282.7M | $249.5M | ||
| Q1 25 | $277.1M | $296.5M | ||
| Q4 24 | $297.1M | $290.3M | ||
| Q3 24 | $279.6M | $283.8M | ||
| Q2 24 | $270.8M | $267.1M | ||
| Q1 24 | $264.4M | $277.0M |
| Q4 25 | $118.1M | $46.7M | ||
| Q3 25 | $66.8M | $42.2M | ||
| Q2 25 | $67.6M | $47.5M | ||
| Q1 25 | $61.1M | $50.1M | ||
| Q4 24 | $87.5M | $61.0M | ||
| Q3 24 | $73.0M | $54.4M | ||
| Q2 24 | $57.6M | $49.1M | ||
| Q1 24 | $59.5M | $49.5M |
| Q4 25 | — | 55.5% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 57.3% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 55.5% | ||
| Q2 24 | — | 54.7% | ||
| Q1 24 | — | 54.8% |
| Q4 25 | 39.2% | 29.1% | ||
| Q3 25 | 33.8% | 29.1% | ||
| Q2 25 | 28.2% | 28.8% | ||
| Q1 25 | 31.2% | 29.8% | ||
| Q4 24 | 36.7% | 31.7% | ||
| Q3 24 | 33.3% | 29.7% | ||
| Q2 24 | 32.0% | 27.0% | ||
| Q1 24 | 29.4% | 29.7% |
| Q4 25 | 35.2% | 16.5% | ||
| Q3 25 | 22.2% | 15.4% | ||
| Q2 25 | 23.9% | 19.0% | ||
| Q1 25 | 22.1% | 16.9% | ||
| Q4 24 | 29.5% | 21.0% | ||
| Q3 24 | 26.1% | 19.2% | ||
| Q2 24 | 21.3% | 18.4% | ||
| Q1 24 | 22.5% | 17.9% |
| Q4 25 | $1.36 | $0.97 | ||
| Q3 25 | $0.93 | $0.86 | ||
| Q2 25 | $0.94 | $0.95 | ||
| Q1 25 | $0.82 | $1.00 | ||
| Q4 24 | $0.99 | $1.22 | ||
| Q3 24 | $1.03 | $1.09 | ||
| Q2 24 | $0.80 | $0.98 | ||
| Q1 24 | $0.84 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $62.4M |
| 总债务越低越好 | $190.0M | $1.0B |
| 股东权益账面价值 | $438.8M | $1.8B |
| 总资产 | $1.6B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.43× | 0.56× |
8季度趋势，按日历期对齐
| Q4 25 | — | $62.4M | ||
| Q3 25 | — | $119.1M | ||
| Q2 25 | — | $139.5M | ||
| Q1 25 | — | $97.9M | ||
| Q4 24 | — | $50.9M | ||
| Q3 24 | — | $51.5M | ||
| Q2 24 | — | $34.3M | ||
| Q1 24 | — | $46.5M |
| Q4 25 | $190.0M | $1.0B | ||
| Q3 25 | $190.0M | $993.1M | ||
| Q2 25 | $200.0M | $992.7M | ||
| Q1 25 | $200.0M | $992.4M | ||
| Q4 24 | $200.0M | $992.0M | ||
| Q3 24 | $200.0M | $1.1B | ||
| Q2 24 | $200.0M | $1.1B | ||
| Q1 24 | $200.0M | $1.1B |
| Q4 25 | $438.8M | $1.8B | ||
| Q3 25 | $402.1M | $1.8B | ||
| Q2 25 | $381.8M | $1.9B | ||
| Q1 25 | $356.5M | $1.8B | ||
| Q4 24 | $388.9M | $1.8B | ||
| Q3 24 | $372.1M | $1.7B | ||
| Q2 24 | $341.2M | $1.7B | ||
| Q1 24 | $320.3M | $1.7B |
| Q4 25 | $1.6B | $3.5B | ||
| Q3 25 | $1.6B | $3.4B | ||
| Q2 25 | $1.4B | $3.4B | ||
| Q1 25 | $1.4B | $3.4B | ||
| Q4 24 | $1.6B | $3.3B | ||
| Q3 24 | $1.6B | $3.3B | ||
| Q2 24 | $1.5B | $3.3B | ||
| Q1 24 | $1.5B | $3.3B |
| Q4 25 | 0.43× | 0.56× | ||
| Q3 25 | 0.47× | 0.54× | ||
| Q2 25 | 0.52× | 0.54× | ||
| Q1 25 | 0.56× | 0.54× | ||
| Q4 24 | 0.51× | 0.55× | ||
| Q3 24 | 0.54× | 0.61× | ||
| Q2 24 | 0.59× | 0.65× | ||
| Q1 24 | 0.62× | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $172.0M | $78.3M |
| 自由现金流经营现金流 - 资本支出 | $171.6M | $75.3M |
| 自由现金流率自由现金流/营收 | 51.2% | 26.6% |
| 资本支出强度资本支出/营收 | 0.1% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.46× | 1.68× |
| 过去12个月自由现金流最近4个季度 | $420.6M | $267.2M |
8季度趋势，按日历期对齐
| Q4 25 | $172.0M | $78.3M | ||
| Q3 25 | $40.4M | $57.5M | ||
| Q2 25 | $50.9M | $79.0M | ||
| Q1 25 | $157.9M | $61.8M | ||
| Q4 24 | $372.8M | $65.1M | ||
| Q3 24 | $112.8M | $69.8M | ||
| Q2 24 | $75.9M | $54.8M | ||
| Q1 24 | $147.0M | $66.9M |
| Q4 25 | $171.6M | $75.3M | ||
| Q3 25 | $40.4M | $55.4M | ||
| Q2 25 | $50.9M | $78.2M | ||
| Q1 25 | $157.7M | $58.4M | ||
| Q4 24 | $371.3M | $63.5M | ||
| Q3 24 | $112.4M | $67.8M | ||
| Q2 24 | $75.2M | $53.6M | ||
| Q1 24 | $146.9M | $63.8M |
| Q4 25 | 51.2% | 26.6% | ||
| Q3 25 | 13.4% | 20.2% | ||
| Q2 25 | 18.0% | 31.3% | ||
| Q1 25 | 56.9% | 19.7% | ||
| Q4 24 | 125.0% | 21.9% | ||
| Q3 24 | 40.2% | 23.9% | ||
| Q2 24 | 27.8% | 20.1% | ||
| Q1 24 | 55.6% | 23.0% |
| Q4 25 | 0.1% | 1.1% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 0.5% | 0.5% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | 0.2% | 0.4% | ||
| Q1 24 | 0.0% | 1.1% |
| Q4 25 | 1.46× | 1.68× | ||
| Q3 25 | 0.60× | 1.36× | ||
| Q2 25 | 0.75× | 1.66× | ||
| Q1 25 | 2.58× | 1.23× | ||
| Q4 24 | 4.26× | 1.07× | ||
| Q3 24 | 1.54× | 1.28× | ||
| Q2 24 | 1.32× | 1.12× | ||
| Q1 24 | 2.47× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APAM
暂无分部数据
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
